Investigators from @danafarber.bsky.social have developed a platform for systematically discovering molecular glues that could become protein degradation drug candidates. Research in @nature.com builds on Ebert & Fischer Lab findings revealing potential to benefit patients w/ cancer. bit.ly/3RACm14

The Mass. Life Sciences Center and @massgovernor.bsky.social named @danafarber.bsky.social to the nation’s first statewide, disease-specific biobank program to support a #ColorectalCancer biobank. Kimmie Ng, MD, says the goal is to advance prevention, early detection, and treatment. bit.ly/4bl6G6s

Dana-Farber Brigham Cancer Center has been recognized as the Best Hospital for Cancer in Massachusetts and ranked #3 in the nation by U.S. News & World Report. Learn more: bit.ly/3TDL9Qi

Peptides are everywhere on social media, with claims that they can speed healing, improve energy, build muscle, and even promote longevity. But for many popular peptides, the hype is far ahead of the science. Learn more about what to know before considering an unapproved peptide. ⬇️

Peptide Safety and Cancer Risk: What You Need to Know

Are peptides safe, and can they increase cancer risk? Learn about unapproved peptides, FDA oversight, potential side effects, and safety concerns.

bit.ly

This year, an estimated 17,370 people in the U.S. will be diagnosed with sarcoma, according to @americancancersoc.bsky.social.   Our healing garden glowed yellow this July for Sarcoma Awareness Month to honor everyone impacted by the disease and help raise awareness. 🎗️ @dfciayasarcoma.bsky.social

We’re proud to share we earned the highest patient-rated nurse communication score among the nation's 11 dedicated cancer hospitals. This recognition reflects both the incredible work of our nurses and the collaborative culture across the Institute that supports an outstanding patient experience.

Nurse communication star ratings for 11 cancer hospitals  - Becker's Oncology

Of all 11 prospective payment system-exempt cancer hospitals, Boston-based Dana-Farber Cancer Institute had the highest nurse communication score between July 1, 2024, and June 30, 2025, according to CMS data published May 13.  The Hospital Consumer Assessment of Healthcare Providers and Systems is a national, standardized survey completed by patients after inpatient hospital stays. Eleven […]

bit.ly

Congratulations to Amin Aalipour, MD, PhD, on being named an inaugural CRI IGNITE Fellow. The IGNITE Award provides up to five years of support that will help advance Aalipour's work on CAR T cell therapies. Learn more ⬇️

Amin Aalipour, MD, PhD - Cancer Research Institute

Chimeric antigen receptor T-cell (CAR T) therapy reprograms a patient’s own immune cells to find and eliminate cancer. While it has transformative for some blood cancers, many patients eventually relapse, and the […]

bit.ly

Join leaders in radiation oncology, medical physics, healthcare operations, and cancer center administration for a multidisciplinary discussion on the emerging role of upright proton therapy. Learn more and register here: bit.ly/4b682BS

Congratulations to Mohammad Rashidian, PhD, on being named a 2026 Cancer Research Institute Lloyd J. Old STAR for his discovery of a signaling hub that unlocks durable, exhaustion-resistant anti-tumor T-cell immunity. Learn more. ⬇️

Introducing the 2026 CRI Lloyd J. Old STARs: Five Scientists Shaping the Future of Cancer Immunotherapy - Cancer Research Institute

Meet the 2026 CRI Lloyd J Old STARs, five bold scientists pushing the boundaries of cancer immunotherapy through high-risk, high-reward research.

bit.ly

The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with “double-positive” metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives. Learn more. ⬇️

Dana-Farber Research Supports FDA Approval of New Therapy for "Double-Positive" Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with "double-positive" metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute

bit.ly

A new tool developed by our investigators could speed diagnostics for acute leukemias, delivering precise results within hours. Learn more. ⬇️

Rapid Epigenetic Test Could Speed Diagnostics for Acute Leukemias

A new epigenetic test could diagnose acute leukemia within hours, helping doctors identify targeted treatment options more quickly.

bit.ly

During Sarcoma Awareness Month, a young adult with Ewing sarcoma shares her experience and why the AYA-focused care provided at Dana-Farber matters. Read her story on the Insight Blog. @danafarber.bsky.social @danafarbernews.bsky.social blog.dana-farber.org/insight/2026...

Doctor by Day, Patient by Night: Young Sarcoma Survivor Overcomes Life Interrupted

From doctor to patient, one young physician shares how an Ewing sarcoma diagnosis reshaped her life, career, and perspective on cancer care.

blog.dana-farber.org

In a recent @natcomms.nature.com publication, @drchoueiri.bsky.social highlights how next-generation HIF-2α inhibitor casdatifan shows promising signs of on-target efficacy in first-in-patient clinical trial in metastatic clear cell kidney cancer. Learn more: bit.ly/4gPUbDB

“There’s a two-way street here. Having these teams and connections going from bench to bedside, back to bench and such, I think will speed up our ability to help patients,” F. Stephen Hodi said about the collaboration behind cancer research and care. Read more. ⬇️

Tracing evolution of vaccine for cancer, malaria — Harvard Gazette

Technology born out of Harvard labs shows the power of collaboration, and how the path to development seldom follows a straight line.

bit.ly

Brian Wolpin, MD, MPH, spoke with @wbur.org Meghna Chakrabarti about promising new research, led by Wolpin and his team, showing daraxonrasib significantly extended survival for patients with previously treated metastatic pancreatic cancer. Listen here. ⬇️

The pill bringing new hope to patients with pancreatic cancer

Pancreatic cancer has long been considered a death sentence. But a revolutionary new treatment has been shown to double survival times.

bit.ly

Congratulations to @amarkelkar.bsky.social for his recent election to the @ama-assn.org Board of Trustees. His focus on prior authorization reform, combatting critical drug shortages, and protecting broad access to care will support patients at Dana-Farber and beyond. ⬇️

AMA announces Board of Trustees for 2026-2027

The 21-members of the AMA Board are introduced.

bit.ly

Get to know Christine Ryan, MD, whose work in lymphoma care and clinical research is helping drive new therapeutic approaches for patients with mantle cell lymphoma. Learn more about her work: bit.ly/4nPMP4a

Our people are our greatest strength. We’re honored to be named to @newsweek.com’s America’s Greatest Workplaces in Health Care 2026 list and are proud to be a workplace where mission, collaboration, and top-notch care come together every day. View the list. ⬇️

America’s Greatest Workplaces in Health Care 2026

In 2026, health care workplaces are evolving amid AI adoption, burnout challenges and staffing shortages, making strong culture more critical than ever.

bit.ly

Could pembrolizumab help improve CAR T-cell therapy outcomes in rare, aggressive B-cell lymphomas? Jennifer Crombie, MD, discusses an ongoing trial exploring this approach before and after CAR T treatment. Learn more about these evolving learnings: bit.ly/4wZiPY2

The face of colorectal cancer is changing. While overall colorectal cancer rates have declined, diagnoses among young adults are rising by 3%, according to a recent study from the American Cancer Society. Here’s what you need to know: bit.ly/3S0Pr3s

Colon Cancer in Young Adults: What You Need to Know

Colon cancer in young adults is on the rise. Find out the latest statistics and the response from healthcare professionals.

bit.ly

Results from the ImmunoPRISM trial reveal that for people with high-risk smoldering multiple myeloma, teclistamab led to deeper responses and helped keep the disease from progressing longer than standard treatment. Learn more. ⬇️

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

In a first-of-its-kind randomized trial, Dana-Farber Cancer Institute researchers found that teclistamab may significantly improve outcomes for patients with high-risk smoldering multiple myeloma, a precursor condition that can progress to active cancer. In the phase 2 ImmunoPRISM trial, the BCMA-targeted bispecific antibody outperformed lenalidomide plus dexamethasone, pointing to the potential value of using immune-based therapy earlier in the course of the disease.

bit.ly

@drmdavids.bsky.social has been selected as the next incumbent of the Harold and Virginia Lash Endowed Chair in Lymphoma Research. Please join us in congratulating him on this well-deserved honor, and in thanking the Lash family for their continued commitment and support.

With more than 150 different variations of sarcoma, a diagnosis is never simple — and can be especially challenging for adolescents and young adults. As care evolves, new treatment options may help reshape what’s possible for AYA patients. Learn more. ⬇️

New Options for Adolescent and Young Adult Patients with Sarcoma 

Published: June 8, 2026Sarcomas are cancers that occur in bone or soft tissue, such as muscles and fat. These cancers are rare and diverse, with more than 150 different variations.  Treatment is advancing for some sarcomas, but most forms of the disease are still treated using chemotherapy, radiation and/or surgery. In some cases, there are few options if the cancer comes back.  Dana-Farber physician-scientists are evaluating innovative ... Read more

bit.ly

.@pewtrusts have selected Xin Gu of @xingulab.bsky.social, along with 20 additional researchers, to join the Pew Scholars Program in the Biomedical Sciences. Please join us in congratulating Gu on this recognition. Read more: bit.ly/4eBIBc9

Dana-Farber Researcher Selected to Join the Pew Scholars Program

The Pew Charitable Trusts announced that Xin Gu, PhD, of Dana-Farber Cancer Institute, is among 21 researchers who have been selected to join the Pew Scholars Program in the Biomedical Sciences. These early-career scientists will receive four years of funding to explore cutting-edge research uncovering insights into human health and disease.

bit.ly

Yesterday, the @fda.gov approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer. This action is based on results from the ASCENT-03 & -04 global clinical trials, which @stolaney1.bsky.social helped to lead. ➡️ bit.ly/4uZoDP0

Congratulations to Benjamin L. Ebert, MD, PhD, and Scott A. Armstrong, MD, PhD, who've been honored with @ash.hematology.org's most prestigious awards and named lectures — recognizing their transformative contributions to research, patient care, and education in blood disorders. Learn more. ⬇️

Two Dana-Farber hematologists receive top honors from the American Society of Hematology

The American Society of Hematology is recognizing 11 distinguished hematologists with its most prestigious awards and named lectures, honoring transformative contributions that have advanced research, patient care, and education in blood disorders. Two of this year's honorees are from Dana-Farber Cancer Institute: Benjamin L. Ebert, MD, PhD, and Scott A. Armstrong, MD, PhD.

bit.ly

As care for newly diagnosed chronic lymphocytic leukemia continues to advance, clinical trials are playing a key role in expanding treatment possibilities. Inhye Ahn, MD, shares the latest updates and what they could mean for patients: bit.ly/4dIVRLH

New Phase 3 results from the BRUIN CLL-322 trial show that for patients whose CLL has returned or stopped responding to treatment, a time-limited 3-drug approach kept the cancer under control longer than standard therapy, without adding much toxicity. Learn more. ⬇️

Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL

Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL

bit.ly

From bench to bedside and back again, the story of menin is just one example of the arc of discovery at Dana-Farber. Learn more about the work that began here two decades ago. ⬇️

Staying One Step Ahead

New insights into how leukemia escapes treatment are shaping smarter combination therapies.

bit.ly

Dr. Mary-Ellen Taplin of @danafarber.bsky.social shares with People Magazine how her personal experience as a patient and caretaker has shaped her commitment to advancing care for patients with #ProstateCancer and advancing research into new treatment approaches. ➡️ bit.ly/3SfSwN8

Woman Was Diagnosed with Cancer and Lost Her Husband to a Brain Tumor. The Tragedies Inspire Her Oncology Work (Exclusive)

A woman was diagnosed with breast cancer amid her late husband's struggles with a fatal brain tumor. The joint health issues inspired Mary-Ellen Taplin's oncology work, she tells PEOPLE exclusively.

bit.ly